Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A De Man

Showing results (401-410 of 480) with videos related to

Pageof 48
Sort By:
Transplant International : Official Journal of the European Society for Organ Transplantation|November 19, 2017
Current policy for allocation of donor livers in the Netherlands advantages primary sclerosing cholangitis patients on the liver transplantation waiting list-a retrospective studyJorn C Goet, Bettina E Hansen, Madelon Tieleman, et al.
Journal of Viral Hepatitis|May 26, 2017
Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B scoreW P Brouwer, A J P van der Meer, A Boonstra, et al.
Journal of Hepatology|November 26, 2020
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severityLisette A P Krassenburg, Raoel Maan, Alnoor Ramji, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2020
Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen lossSylvia M Brakenhoff, Robert A de Man, André Boonstra, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|March 26, 2016
Seroprevalence of Hepatitis E Virus in Autoimmune Hepatitis Patients in the NetherlandsNicole M F van Gerven, Annemiek A van der Eijk, Suzan D Pas, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2005
The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuationM van Zonneveld, H J Flink, E Verhey, et al.
Liver Cancer|October 12, 2019
Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with SorafenibTim A Labeur, Jeroen L A van Vugt, David W G Ten Cate, et al.
Lancet (London, England)|January 11, 2005
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trialHarry L A Janssen, Monika van Zonneveld, Hakan Senturk, et al.
Nature Communications|December 10, 2021
A turquoise fluorescence lifetime-based biosensor for quantitative imaging of intracellular calciumFranka H van der Linden, Eike K Mahlandt, Janine J G Arts, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|August 8, 2022
End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patientsSylvia M Brakenhoff, Robert J de Knegt, Margo J H van Campenhout, et al.
Pageof 48

Showing results (401-410 of 480) with videos related to

Sort By:
Pageof 48
Transplant International : Official Journal of the European Society for Organ Transplantation|November 19, 2017
Current policy for allocation of donor livers in the Netherlands advantages primary sclerosing cholangitis patients on the liver transplantation waiting list-a retrospective studyJorn C Goet, Bettina E Hansen, Madelon Tieleman, et al.
Journal of Viral Hepatitis|May 26, 2017
Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B scoreW P Brouwer, A J P van der Meer, A Boonstra, et al.
Journal of Hepatology|November 26, 2020
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severityLisette A P Krassenburg, Raoel Maan, Alnoor Ramji, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2020
Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen lossSylvia M Brakenhoff, Robert A de Man, André Boonstra, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|March 26, 2016
Seroprevalence of Hepatitis E Virus in Autoimmune Hepatitis Patients in the NetherlandsNicole M F van Gerven, Annemiek A van der Eijk, Suzan D Pas, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2005
The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuationM van Zonneveld, H J Flink, E Verhey, et al.
Liver Cancer|October 12, 2019
Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with SorafenibTim A Labeur, Jeroen L A van Vugt, David W G Ten Cate, et al.
Lancet (London, England)|January 11, 2005
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trialHarry L A Janssen, Monika van Zonneveld, Hakan Senturk, et al.
Nature Communications|December 10, 2021
A turquoise fluorescence lifetime-based biosensor for quantitative imaging of intracellular calciumFranka H van der Linden, Eike K Mahlandt, Janine J G Arts, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|August 8, 2022
End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patientsSylvia M Brakenhoff, Robert J de Knegt, Margo J H van Campenhout, et al.
Pageof 48